Birth control that uses combined hormones raises heart risk: study

June 13, 2012 By Maureen Salamon, HealthDay Reporter
Birth control that uses combined hormones raises heart risk: study
Overall odds of heart attack and stroke, however, are still low.

(HealthDay) -- Sweeping new research comparing various forms of hormonal contraception -- including birth control pills, vaginal rings and skin patches -- suggests that the risk for heart attacks and strokes is twice as high among users of combined estrogen-progestin versions.

These include brands such as Yasmin and Yaz pills, the NuvaRing vaginal ring and Ortho Evra patches. The overall odds of suffering such debilitating effects, however, are still quite low.

Analyzing 15 years of from more than 1.6 million women aged 15 to 49, Danish scientists found that those taking low-dose estrogen combined with various progestins suffered heart attacks and strokes between 1.5 and 2 times more often than women not using hormonal contraception. The risks were between 2.5 and 3 times higher among users of vaginal rings and transdermal patches compared to non-users.

"The first point to take home is that [clotting] complications increase dramatically with increasing age," said lead author Dr. Ojvind Lidegaard, a clinical professor of at Rigshospitalet, a state-run hospital in Copenhagen. "A doubled risk for thrombotic stroke is not very serious when you are 20 years old, because your risk at baseline is very low. On the other hand, when you are 35 years old or older, the risk is no longer that low, and you should be more careful with choosing those products with the lowest risk of thrombotic complications."

The study is scheduled to be published June 14 in the .

The link between combined estrogen-progestin and occurring in either veins or arteries has been studied continually since the formulations were marketed in the 1960s, with estrogen doses lowered in many products in response to research showing increased vascular risks.

The U.S. announced in April that pills containing drospirenone -- a man-made version of the hormone progesterone included in products such as Bayer's Yaz or Yasmin -- would require updated labels since these contraceptives may be linked to a higher risk of blood clots. That change pinpointed risks associated with blood clots in veins, however, while the new Danish study focuses on clot risks in arteries.

"Pills are still very beneficial. I wouldn't want a study like this ... to tell us these are dangerous drugs," said Dr. Kathleen Hoeger, chief of the division of reproductive endocrinology and director of the Strong Fertility Center at the University of Rochester, in New York. "The drugs have risks, and those risks are really well-defined. This data gives doctors a lot of confidence to be able to offer advice."

The study encompasses data from the entire population of Danish women of childbearing age, and was 10 times as large as a similar study in the United States that also assessed the comparative risks of arterial clots among hormonal contraceptive users, said Hoeger, who served on the FDA advisory panel that reviewed Yaz and Yasmin.

Significantly higher rates of heart attack and stroke, which result from clots in arteries, were recorded among women with diabetes and high blood pressure and among those over age 35. The relative odds of suffering a doubled among those aged 40 to 44 compared to those aged 35 to 39, and increased by an additional one-third thereafter.

Dr. Diana Petitti, a professor of biomedical informatics at Arizona State University in Tempe, said she was struck by the finding that different formulations of progestin didn't dramatically affect the safety profiles of the various hormonal contraceptives studied.

"From the standpoint of arterial vascular disease, the combined [formulations] are essentially equivalent," said Petitti, who wrote an editorial accompanying the study. "Decision-making should focus more on effectiveness and adherence and not on miniscule differences in the potential for vascular disease. All of the current products on the market are safe enough."

Explore further: Some birth control shows higher clot risk: US

More information: The U.S. National Library of Medicine has more about oral contraceptives.

Related Stories

Some birth control shows higher clot risk: US

October 28, 2011
Some birth control products, including contraceptive pills, rings and patches for women, carry a significantly higher risk of blood clot than low-dose medications, US regulators said Thursday.

Certain birth control pills may carry higher blood clot risk: FDA

April 10, 2012
(HealthDay) -- U.S. health officials announced Tuesday that birth controls pills containing drospirenone -- a man-made version of the hormone progesterone -- may be associated with a higher risk of blood clots and will require ...

Study adds to evidence on clot risks of non-oral contraceptives

May 10, 2012
A study published on BMJ website today adds to the evidence that certain non-oral hormonal contraceptives (e.g. skin patches, implants and vaginal rings) carry a higher risk of serious blood clots (known as venous thromboembolism) ...

FDA ties newer birth control drugs to blood clots

October 27, 2011
(AP) -- Safety concerns with the popular birth control pill Yaz increased Thursday as federal health scientists reported that the Bayer drug and other newer birth control treatments appear to increase the risk of dangerous ...

FDA panel backs birth control patch despite risks

December 10, 2011
(AP) -- A panel of federal health advisers said Friday that a birth control patch from Johnson & Johnson probably carries a higher risk of blood clots than older drugs, but should remain available as an option for women ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tthb
not rated yet Jun 13, 2012
where will others get supply of 'hormones' later, if 'they' no longer supply it? . . . . two wires & a battery, QUICK, while the Sun Shines still-

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.